Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK-triggered Expansion Cohort

NCT06072586 is registered in ClinicalTrials.gov with St. Joseph's Hospital and Medical Center, Phoenix as lead sponsor.

NCT NCT06072586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06072586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK-triggered Expansion Cohort
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Phase
Phase 1
Overall status
Recruiting
Start date
October 18, 2023
Completion date
December 31, 2027
Enrollment
82 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, high grade glioma